Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13

Authors: Juan Sendon-Lago, Samuel Seoane, Noemi Eiro, Maria A. Bermudez, Manuel Macia, Tomas Garcia-Caballero, Francisco J. Vizoso, Roman Perez-Fernandez

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

After the publication of this work [1] an error was noticed in Fig. 4d and 4f. In the migration and invasion assays the same image was used accidentally for the Pit-1 + shMMP-1 and Pit-1 + shMMP-13. The corrected figure is shown below. The error does not affect the findings or conclusion of the article. We apologize for this error.
Literature
1.
go back to reference Sendon-Lago J, Seoane S, Eiro N, Bermudez MA, Macia M, Garcia-Caballero T, Vizoso FJ, Perez-Fernandez R. Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13. Breast Cancer Res. 2014;16:505.CrossRefPubMedPubMedCentral Sendon-Lago J, Seoane S, Eiro N, Bermudez MA, Macia M, Garcia-Caballero T, Vizoso FJ, Perez-Fernandez R. Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13. Breast Cancer Res. 2014;16:505.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13
Authors
Juan Sendon-Lago
Samuel Seoane
Noemi Eiro
Maria A. Bermudez
Manuel Macia
Tomas Garcia-Caballero
Francisco J. Vizoso
Roman Perez-Fernandez
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0834-5

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine